Ottiliavej 9 Tel +45 36 30 13 11 DK-2500 Valby København Fax +45 36 43 82 62



Release No 266

24 April 2007

H. Lundbeck A/S held its Annual General Meeting on 24 April 2007 as SAS Radisson Falconer Hotel & Conference Center

At the general meeting note was taken of the report by the Supervisory Board on the activities of the company during the previous year, the Annual Report was approved, and the Supervisory Board and Executive Management were discharged from liability.

The general meeting approved the dividend of 1.57 per share of DKK 5 nominal value proposed by the Supervisory Board.

Flemming Lindeløv, Thorleif Krarup, Peter Kürstein, Mats Pettersson and Jes Østergaard were all re-elected to the Supervisory Board. Lars Bruhn resigned from the Supervisory Board, and Per Wold-Olsen was elected as a new member. Immediately after the general meeting the Supervisory Board elected Flemming Lindeløv Chairman and Thorleif Krarup Deputy Chairman of the Supervisory Board.

After having elected its Chairman and Deputy Chairman, the Supervisory Board appointed members for the Audit Committee and the Compensation Committee.

Peter Kürstein, Flemming Lindeløv and Thorleif Krarup were re-elected members of the Audit Committee. Flemming Lindeløv, Mats Pettersson and Jes Østergaard were elected members of the Compensation Committee.

The Supervisory Board of H. Lundbeck A/S will hereafter comprise:

- Flemming Lindeløv
- Thorleif Krarup
- Peter Kürstein
- Mats Pettersson
- Per Wold-Olsen
- Jes Østergaard
- Birgit Bundgaard Rosenmeier (elected by the employees)
- William Patrick Watson (elected by the employees)
- Kim Rosenville Christensen (elected by the employees)

H. Lundbeck A/S

Ottiliavej 9 Tel +45 36 30 13 11 DK-2500 Valby København Fax +45 36 43 82 62

E-mail investor@lundbeck.com www.lundbeck.com

Deloitte Statsautoriseret Revisionsaktieselskab and Grant Thornton Statsautoriseret Revisionsaktieselskab were re-elected auditors for the company.

The Supervisory Board's proposed resolutions under item 6 of the agenda were adopted. Consequently, a resolution was adopted to reduce the company's share capital by reducing the company's holding of treasury shares acquired from shareholders of the company, including as part of the implementation of share buyback programmes. Article 7(1), first sentence of the Articles of Association was amended as a consequence of the Danish municipal reform so that the company's general meeting will be held in the Capital Region in the future. The Supervisory Board was further authorised to arrange for the acquisition of treasury shares by the company pursuant to s. 48 of the Danish Public Companies Act. Finally, the chairman of the general meeting was authorised to make such changes in and supplements to the resolutions adopted by the general meeting and the notification to the Danish Commerce and Companies Agency as may be requested by the Commerce and Companies Agency in connection with its registration of the amendments made.

No other business was transacted at the general meeting.

The Supervisory Board

The content of this release will have no influence on the Lundbeck Group's financial result for 2007.

Lundbeck contacts

Steen Juul Jensen Vice President +45 36 43 30 06

Investors: Media:

Mads Bjerregaard Pedersen Caroline Broge
Investor Relations Officer Media Relations Manager
+45 36 43 41 04 +45 36 43 26 38

Jacob Tolstrup Investor Relations Manager, North America +1 201 350 0187 Ottiliavej 9 Tel +45 36 30 13 11 DK-2500 Valby København Fax +45 36 43 82 62



Stock Exchange Release No 266 - 24 April 2007

About Lundbeck

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com